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Abstract
Medication overuse in primary headache disorders is a worldwide phenomenon and has a role in the chronification of
headache disorders. The burden of disease on individuals and societies is significant due to high costs and comorbidities.
In the Third Edition of the International Classification of Headache Disorders, medication-overuse headache is recognized
as a separate secondary entity next to mostly primary headache disorders, although many clinicians see the disease as a
sole complication of primary headache disorders. In this review, we explore the historical background of medication-
overuse headache, its epidemiology, phenomenology, pathophysiology and treatment options. The review explores
relevant unanswered questions and summarizes the current debates in medication-overuse headache.
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Background
Overuse of symptomatic medication is a common problem
in patients with primary headache syndromes [1, 2]. Head-
ache syndromes such as migraine or tension-type headache
cause painful experiences and significant disability in pa-
tients. The use of analgesics is therefore justifiable when
correctly utilized. For more than 50 years, clinicians have
recognized and reported on headache chronification oc-
curring during a period of frequent use of analgesics. The
underlying consensus for the entity of medication-overuse
headache (MOH) consists of a deterioration of a
pre-existing headache syndrome whilst overusing one or
several types of acute painkilling treatments. MOH is
widely accepted and recognised in the neurological and
headache community nowadays, although the entity
keeps raising important questions. Debates on the
pathophysiological mechanisms, definitions of overuse
and the nosology of MOH are ongoing. This review
presents the current state of literature and knowledge
on MOH. It provides an overview of the history,
clinical features, epidemiology of MOH, an update on
the current understanding of the underlying
neurobiological mechanisms and treatment, before
discussing the key topics in the controversies sur-
rounding MOH.
MOH in historical perspective
The first descriptions of MOH date back to 1930s, when
multiple authors started to associate prolongation of mi-
graine with ergotamine-overuse [3–8]. Chronic headache
following overuse of ergotamine was clearly defined by Pe-
ters and Horton in 1951 [9]. They reported on 52 migraine
patients who developed daily headache after daily use of
ergotamine and noted improvement after the drug was
stopped. The same authors published their withdrawal
protocol in 1963 [10]. The first ergotamine withdrawal
protocols were proposed independently by Graham,
Friedman and Lippmann in 1955 [3, 6–8]. In the 1970s,
multiple authors wrote on the association between overuse
of mixed analgesics, including those based on ergotamine,
barbiturates and codeine, and headache progression [11,
12]. In 1982, Mathew et al. outlined that overuse of
analgesics contributed to the transformation of episodic
migraine (EM) into daily headaches and a few years later
the same group introduced the term “transformed or
evolutive migraine” to describe the entity [3, 13, 14].
The first edition of the International Classification of
Headache Disorders (ICHD) was published in 1988
which introduced the term “drug-induced headache”. It
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also introduced and specified the entities “ergotami-
ne-induced headache”, “analgesics abuse headache”
and “other substances” [15]. This was based on the
experience with overuse of analgesics and ergots only.
After the introduction of triptans, it became clear
that this class of drugs could also induce headache
deterioration if used excessively [16–18]. In 1994 Sil-
berstein et al. proposed criteria for “transformed mi-
graine”, since transformation of EM to daily or
almost-daily head pain (> 15 days/month) was
associated with medication overuse [3, 19].
The term “medication-overuse headache” was first
introduced in the second edition of the ICHD in
2004 [20]. It also defined MOH subtypes induced by
simple analgesics, combination-analgesics, ergots, trip-
tans and opioids. The diagnostic criteria included a
mandatory prerequisite that the headache syn-
drome resolved or reverted to the previous pattern
within 2 months after discontinuation of the overused
drug. This caused the entity of definite MOH to be
diagnosed retrospectively and more difficult to handle
in clinical practice [20]. The criterion was changed in
2006 when a board of experts published revisions by
consensus and introduced a broader concept of
MOH, in which the diagnosis was based on headache
frequency (equal to or greater than 15 days/month)
and overuse of headache medication, but did not re-
quire the headache to improve after withdrawal [21].
This criterion was omitted again in the latest and
current Third Edition of the International Classifica-
tion of Headache Disorders (ICHD-3) [22].
Current definitions
In ICHD-3, chronic headache syndromes are defined by
expert consensus as headache disorders that share char-
acteristics with pre-existing headache syndromes, occur
for a certain amount of time (at least 3 months in e.g.
chronic tension-type headache (CTTH), chronic mi-
graine (CM); or at least 1 year in e.g. chronic trigeminal
autonomic cephalalgia (TAC)) and have an additional
time-criterion (e.g. headache days per month in CTTH
and CM, or the absence of remissions for more than 3
months in TAC’s). MOH is found in ICHD-3 under
subsection 8.2 as a chronic headache disorder second-
ary to a pre-existing headache syndrome. It is stipulated
as a consequence of regular overuse of drugs for the
acute treatment of headache. To establish the diagnosis,
patients have to use symptomatic headache medication on
more than 10 or more than 15 days per month, depending
on the drug class, for more than 3 months. MOH has 8
subforms – MOH induced by ergotamine, triptans, analge-
sics including paracetamol, aspirin and other non-steroidal
anti-inflammatory drugs (NSAIDs), opioids, combination
analgesics, unspecified multiple drug classes and others
(Table 1) [22].
Although considered a general rule in the past, it is
now well stated in the classification that MOH usually,
but not invariably, resolves once the overuse is stopped
[22, 23]. As with all secondary headache syndromes in
ICHD-3, there is no longer a necessary requirement of
remission or substantial improvement of the underlying
causative disorder for the diagnosis to be made. There-
fore, when MOH is confirmed by using the medical his-
tory of the patient, a two-fold diagnosis is made: the first
one entailing the primary headache syndrome that re-
sulted in drug overuse, the second one MOH [23].
Epidemiology
The prevalence of chronic headache is 4% to 5%, with an
incidence of 3% per year [24, 25]. The incidence of
new-onset CM in patients with EM is around 2.5% per
year [24, 26]. Even higher incidence rates up to 14%
were reported from a tertiary centre [27]. Prevalence
rates for MOH in the general population level are situ-
ated between 1 and 2%, with a range between 0.5% and
7.2% [28]. The highest prevalence has been shown in
Russia (7.2%) [29]. Knowledge about prevalence and
socio-economic burden in lesser developed countries
has been very limited for a long time, although studies
have been published lately for prevalence in Africa
(Zambia 7.1%; Ethiopia 0.7%), Latin America (Brazil
1.4%, Colombia 4.3%) and Asia (Korea 0.5%; China 0.6%)
[30–35] . MOH is estimated to affect around 63 million
people worldwide [35–37]. The prevalence of medication
overuse is higher in studies from headache specialist
centers, with numbers ranging from 30% to 50% of pa-
tients [38–40].
A systematic review of epidemiological studies found
that MOH is most common among middle-aged adults
from 30 to 50 years of age, and predominant in females
in the majority of studies. The male to female ratio is
around 1 to 3–4 [28, 36, 41–43]. Among U.S. children
and adolescents, the prevalence of CM was found to be
0.79% if medication overuse was excluded, and 1.75% if
it was included [44, 45]. Prevalence of MOH was greater
in girls than boys [44]. Furthermore, between 21% and
52% of pediatric patients with chronic headache met the
criteria for MOH [45, 46]. Worldwide, the prevalence of
MOH in pediatric samples was 3.3%, 0.3%, 0.5% and
1.6% in Italy, Taiwan, Norway and Canada respectively
[37, 47–50]. In the elderly population, studies from mul-
tiple headache centers found that around 35% of patients
older than 64 years were overusing medication [51, 52].
Reports on prevalence of MOH in specific populations
and minorities have been published. In Europe, certain
minorities or ethnic groups, such as first-generation
migrants, show higher than expected rates of MOH.
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Potential explanations for these findings include socioeco-
nomic (e.g. use of healthcare), biological (e.g. genetic) or
cultural reasons (e.g. language barriers) [53].
The burden of disease for MOH has been shown to be a
worldwide problem. The disorder causes important nega-
tive social and economic effects in both rich and poor
countries. Mean per-person annual costs were calculated
at €3561 for medication overuse [54]. Not only economic
factors, but also psychological and physical disability of
chronic headache and MOH needs to be considered. The
global campaign “Lifting the Burden” has contributed to
the acquisition of new data and to the promotion of accur-
ate epidemiological methods all over the world [55, 56]. In
the most recent issue of the Global Burden of Disease
(GBD) in 2016, migraine became the second largest cause
of disability, mainly because MOH was considered a
sequela of migraine and tension-type headache [57].
Risk factors
Medication overuse was found to be an important risk
factor for chronification of primary headaches [58]. A
systematic review analysed twenty-nine studies and
found differences in the risk of developing MOH and
the type of used drug. The risk was lowest for triptans
(relative risk (RR) 0.65) and ergotamine (RR 0.41) com-
pared to combined analgesics. Triptans and ergotamine
containing drugs were found more favorable when com-
pared to opioids [59]. This is in line with Bigal et al. who
reported that people using medication containing barbi-
turates or opiates had a two-fold higher risk of develop-
ing chronic headache than patients using single
analgesics or triptans. In this study, NSAIDs were pro-
tective against developing chronic headache at low to
moderate level of monthly headache days, but were asso-
ciated with an increased risk of developing chronic head-
ache in patients with a high level of monthly headache
days (more than 10 days per month) [26].
An important risk factor for the development of MOH
is predisposition for migraine or tension-type headache
as an underlying biological trait. Migraine is the most
common pre-existing headache disorder complicated by
MOH. Other pre-existing headache disorders can be
complicated by MOH as well, such as tension-type head-
ache or cluster headache [60]. Paemeleire et al. investi-
gated the presence of MOH in patients suffering from
Table 1 International Classification of Headache Disorders Third
Edition (ICHD-3) Criteria for Medication-Overuse Headache
(MOH) [22]
8.2 Medication-overuse headache (MOH)
A. Headache occurring on ≥15 days/month in a patient with a
pre-existing headache disorder
B. Regular overuse for > 3 months of one or more drugs that
can be taken for acute and/or symptomatic treatment of
headache
C. Not better accounted for by another ICHD-3 diagnosis.
8.2.1 Ergotamine-overuse headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of ergotamine on ≥10 days/month for >
3 months.
8.2.2 Triptan-overuse headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of one or more triptans,1 in any formulation,
on ≥10 days/month for > 3 months.
8.2.3 Non-opioid analgesic-overuse headache
8.2.3.1 Paracetamol (acetaminophen)-overuse headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of paracetamol on ≥15 days/ month for >
3 months.
8.2.3.2 Non-steroidal anti-inflammatory drug (NSAID)- overuse
headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of one or more non-steroidal anti-
inflammatory drugs (NSAIDs) (other than acetylsalicylic
acid) on ≥15 days/month for > 3 months.
8.2.3.2.1 Acetylsalicylic acid-overuse headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of acetylsalicylic acid on ≥15 days/ month
for > 3 months.
8.2.3.3 Other non-opioid analgesic-overuse headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of a non-opioid analgesic other than
paracetamol or non-steroidal anti-inflammatory drugs
(including acetylsalicylic acid) on ≥15 days/month for
> 3 months.
8.2.4 Opioid-overuse headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of one or more opioids on ≥10 days/month
for > 3 months.
8.2.5 Combination-analgesic-overuse headache
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of one or more combination-analgesic
medications on ≥10 days/month for > 3 months.
8.2.6 Medication-overuse headache attributed to multiple drug
classes not individually overused
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular intake of any combination of ergotamine, triptans,
non-opioid analgesics and/or opioids on a total of ≥10
days/month for > 3 months without overuse of any single
drug or drug class alone.
8.2.7 Medication-overuse headache attributed to unspecified or
unverified overuse of multiple drug classes
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Both of the following: 1. regular intake of any combination
of ergotamine, triptans, non-opioid analgesics and/or opioids
on ≥10 days/month for > 3 months
Table 1 International Classification of Headache Disorders Third
Edition (ICHD-3) Criteria for Medication-Overuse Headache
(MOH) [22] (Continued)
8.2.8 Medication-overuse headache attributed to other medication
A. Headache fulfilling criteria for 8.2 Medication- overuse
headache
B. Regular overuse, on ≥10 days/month for > 3 months, of
one or more medications other than those described above,
1 taken for acute or symptomatic treatment of headache.
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cluster headache and found this complication only in pa-
tients also suffering with migraine or having at least a fam-
ily history of migraine [61]. In addition, the clinical
experience shows that the majority of patients suffering
from cluster headache do not complicate into MOH al-
though overuse of sumatriptan injections can lead to in-
creased frequency of cluster attacks [62]. Patients with
other chronic pain disorders who overuse painkillers for
non-cephalic pain conditions do not seem to acquire
chronic headache, unless they have a pre-existing history
of a primary headache disorder [63, 64].
In a large prospective population-based study, Hagen et
al studied 25.596 patients who did not suffer from chronic
daily headache at baseline but had MOH 11 years later (n
= 201, 0.8%) [65]. In this study, the following risk factors
were found to be associated with the development of
MOH: regular use of tranquilizers (odds ratio (OR) 5.2,
95% confidence interval (CI) 3.0–9.0), combination of
chronic musculoskeletal complaints, gastrointestinal
complaints and Hospital Anxiety and Depression Scale
(HADS) score > = 11, physical inactivity (defined as > =
3 h hard physical activity/week), and smoking (daily vs.
never). Furthermore, migraine was a stronger risk factor
for MOH than nonmigrainous headache. A strong associ-
ation was found for a high-frequency headache defined as
7–14 days/months compared to absence of headache days.
Non-modifiable risk factors for MOH were age younger
than 50, female gender and low level of education. Inter-
estingly, the authors found several risk factors for MOH
(e.g. smoking, inactivity) that were not found to increase
the risk for chronic daily headache without the overuse of
analgesics. Therefore, the authors concluded that both en-
tities might be pathogenetically distinct [65]. Lastly, Cevoli
et al. detected a more than threefold increased risk of
MOH if a family history of MOH or other substance
abuse, such as drug or alcohol abuse, was present [66].
Clinical features of MOH
A comprehensive medical history, clinical examination
and the use of internationally accepted criteria and guide-
lines are the required tools for the diagnosis of MOH. A
confirmatory diagnostic test for MOH is currently not
available. The headache phenotype of MOH may be indis-
tinguishable from other forms of chronic daily headache.
Moreover, the ICHD-3 criteria do not stipulate
MOH-specific clinical features (such as headache charac-
teristics or associated symptoms). Awareness for potential
secondary headache syndromes is required and ‘red flags’
have to be searched for in order to the avoid a
false-positive diagnosis of MOH in escalating headache
disorders, some of which may require medical imaging or
lumbar puncture. In practice, an in-depth enquiry of head-
ache types, frequency and especially drug use is always
mandatory, as overuse of ergotamine, triptans, NSAIDs,
opioids, or analgesic combinations entail different prog-
nostic properties [24, 67].
Comorbidities
Comorbidity is the simultaneous existence of two or
more different medical conditions. Comorbidities occur
by chance, or by more than chance, suggesting a poten-
tial association, causality, common aetiological factors or
common pathophysiological processes. In the field of
MOH, these terms are often difficult to appoint although
researchers have found multiple associations.
Psychiatric comorbidities in MOH are frequent
and have been studied extensively since the earliest de-
scriptions of patients with MOH [68]. MOH and mood
disorders such as anxiety and depression are thought to
be comorbid disorders by more than chance [13, 69–71].
In the BIMOH study, a prospective interventional study,
Hospital Anxiety and Depression Scale (HADS) scores
were collected in patients with MOH (before and after a
brief intervention) and controls. MOH patients were
found to show significantly higher HADS scores for anx-
iety [72]. In the “COMOESTAS” trial, using HADS,
40.0% of MOH patients fulfilled the criteria for depres-
sion and 57.7% for anxiety [73]. The “Eurolight” trial, a
cross-sectional study in the adult population of ten
European Union countries, found similar results. The as-
sociation was even stronger compared to a group of pa-
tients with migraine without overuse [74].
In the Sodium Valproate in Medication Overuse Head-
ache Treatment (SAMOHA) study, a more extensive
screening for psychopathological comorbidities was per-
formed in MOH patients in comparison to patients with
EM and healthy controls [71]. The rate of moderate to se-
vere anxiety in MOH was significantly higher compared to
EM patients and healthy controls. Values on the Leeds De-
pendency Questionnaire were significantly higher in MOH
patients compared to EM patients, which indicates a
greater susceptibility to drug dependency. When looked at
the number of psychiatric disorders, MOH patients were
more likely to have multiple psychiatric comorbidities.
An association between clinically relevant
obsessive-compulsive disorder (OCD) and MOH was
demonstrated [71]. Around 30% of MOH patients are esti-
mated to show clinical features of subclinical OCD on
neuropsychological evaluation. Subclinical OCD may be
an additional risk factor for headache chronification [75,
76]. Also, MOH can be associated to substance-related
disorder spectrum, moreover since MOH and dependence
share common neurobiological pathways, although MOH
patients do not share common personality characteristics
with drug addicts [77, 78].
For metabolic disorders, a couple of studies from North
America on obesity found an increased risk of developing
chronic headache, although in the European study by
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Hagen et al. no such association found [69, 79, 80]. In a
Chinese cohort, an association between MOH and meta-
bolic disturbances such as obesity and hypertension was
shown in female patients [81]. Recent data on smoking,
physical inactivity and obesity provided by a Danish
cross-sectional analysis confirmed an association between
MOH and those metabolic derangements although causal-
ity could not be proven [82]. In children, the association
between obesity and chronic headache has been shown in
observational studies, but the link with medication over-
use is unclear [83, 84]. Lastly, patients with chronic head-
ache and MOH present a high prevalence of sleep
complaints [85].
Pathophysiology
A complete understanding of the pathophysiology of
MOH currently does not exist [86–88]. Although the
clinical aspects of MOH seem to be ambivalent, there is
evidence for specific neurobiological aspects in
MOH-models. Animal studies, genetic studies, structural
and functional neuroimaging, and electrophysiological
analyses have added to the current knowledge on the
pathophysiology of MOH (Fig. 1).
Animal studies have shown changes in multiple physio-
logical processes in the central nervous system (CNS)
after repetitive administration of analgesics. Chronic su-
matriptan exposure produces long-lasting increased sus-
ceptibility to evoked cortical spreading depression (CSD)
due to lower threshold [89–91]. Upregulation of
vaso-active and pro-inflammatory mediators such as calci-
tonin gene–related peptide (CGRP), substance P, and ni-
tric oxide synthase were found in trigeminal ganglia [92,
93]. An expansion of the receptive nociceptive field, a de-
creased nociceptive threshold and decreased noxious in-
hibitory control have been reported [91, 94]. Furthermore,
chronic exposure to analgesics was found to increase the
excitability of neurons in the central nucleus of the amyg-
dala, which may conceptualise the development of anxiety
or depression in patients with MOH [95].
The serotonergic modulating system is presumably
affected by chronic analgesic use, resulting in neuronal hy-
perexcitability, enhanced CSD and trigeminal nociception,
caused by increased expression of pro-nociceptive sero-
tonin 2A (5HT-2A) receptor binding sites and a decrease
in the production of serotonin in the CNS [96–98]. In ana-
logy to the findings in animals, an upregulation of 5HT-2
receptors on platelet membranes during analgesic abuse
and lower platelet levels of serotonin were found, probably
caused by suppressed serotonin transport [99].
Genetic studies have been performed in MOH although
high-quality evidence for genetic traits is currently lacking.
In a recent systematic review, Cargnin et al. described
candidate polymorphic variants in genes of the dopamin-
ergic gene system (DRD4, DRD2, SLC6A3), and genes re-
lated to drug-dependence pathways (WSF1, BDNF, ACE,
HDAC3). The authors concluded that these traits are
Fig. 1 Current understanding of the pathophysiology of medication-overuse headache (MOH). The knowledge on the pathophysiology of MOH
involves conversion from and reversion to primary headache disorders, showing changes in physiological processes, functional connectivity and
structural changes of the central nervous system, in patients with underlying genetic susceptibility. Abbreviations: MOH: medication-overuse
headache; CNS: central nervous system
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potential risk factors for MOH susceptibility or determi-
nants of monthly drug consumption [100–107].
Research shows that central sensitization has a major
role in the pathophysiology of MOH [88, 108]. Using som-
atosensory evoked potentials comparing cortical responses
in MOH patients with responses in healthy volunteers and
episodic migraineurs, hypersensitivity (a sign of central
sensitization) and hyper-responsiveness of the cerebral
cortex were shown in MOH patients as potential markers
of altered functioning. The authors suggested that the
somatosensory cortex in MOH patients is somehow
“locked” in a kind of pre-ictal state [109, 110].
More recently, a cohort of MOH patients was followed
during a 12 month period, evaluating central
sensitization through pain-perception assessment. The
authors found evidence of central sensitization at base-
line, but most importantly, the study permitted to
expose the slow progression towards normalization of
sensory processing after detoxification during the ex-
tended follow-up window. This adds to the importance
of detoxification and observation after withdrawal in
order to prevent relapses [111].
Over the last decade, imaging studies have increased the
knowledge of structural alterations and physiological
events in MOH. Structural imaging studies performed by
separate groups have found increased gray matter volume
in following areas: periaqueductal gray (PAG) area, poster-
ior cingulate cortex, hippocampus, thalamus, fusiform
gyrus, cerebellum and ventral striatum [87, 88, 112]. Less
volume was found in the orbitofrontal cortex (OFC), anter-
ior cingulate cortex, left middle occipital gyrus, insula and
precuneus [87, 88, 112]. These structures are involved in
pain modulation and processing, cognition, affective behav-
ior, addiction and awareness [87]. A recent study described
disturbances in white matter integrity in the insular cortex
and in the parietal operculum [113]. It has to be noted
however that not all studies found the same morphologic
differences in the brains of MOH patients with migraine,
including those comparing scans before and after with-
drawal [87, 114, 115].
Functional imaging has shown altered functional con-
nectivity in pain processing areas, the mesocorticolimbic
‘reward’ system, the salience network, the fronto-parietal at-
tention network, the default network and memory process-
ing networks [87, 113, 115–118]. The mesocorticolimbic
dopaminergic ‘reward’ system, characterized by structures
such as the ventromedial prefrontal cortex (VMPFC), the
nucleus accumbens and the substantia nigra/ventral teg-
mental area, seems to be affected in MOH, linking psychi-
atric characteristics such as dependence mechanisms and
addictive components to the disorder [87, 117, 118].
It is noteworthy that, in MOH, changes of functional
connectivity and structure may be reversible in some but
not all regions and sometimes normalize after treatment
[87]. By using [18F] fluorodeoxyglucose-Positron emission
tomography (FDG-PET), it was detected how several pain
processing regions in the brain were hypometabolic dur-
ing medication overuse but recovered to normal metabol-
ism after withdrawal. An exception to these findings was
found in the OFC, a region linked with drug dependence
and addiction. This region remained hypometabolic des-
pite discontinuation of analgesics [119]. Other groups
have confirmed changes in this region of interest. Reduc-
tion of gray matter volume in the OFC was correlated
with headache days at follow-up, hereby exhibiting pre-
dictive capability in terms of poor response to treatment
[112, 120]. Non-responders to withdrawal therapy seemed
to have less gray matter in the OFC on their
pre-detoxification scan and that there was a positive cor-
relation of gray matter in the OFC with response to treat-
ment [121]. Interestingly, in a longitudinal study, MOH
patients with clinical improvement after withdrawal had a
significant decrease of previously increased gray matter in
the midbrain (PAG, nucleus cuneiformis), whereas pa-
tients without improvement did not [121]. Another group
found that VMPFC dysfunction is reversible and might be
attributable to headache, whereas dysfunction observed in
the mid-brain dopaminergic areas (substantia nigra/ven-
tral tegmental area) are probably long-lasting and related
to drug overuse [116, 117]. In conclusion, the evidence
provided in multiple studies shows that medication over-
use causes changes to the CNS in people with an under-
lying susceptibility for progression. Changes in pain
processing networks, dependence networks, sensitization
and receptor density in the CNS presumably explain the
clinical characteristics of the disorder.
Treatment
Education and prevention
MOH is often considered to be a preventable condition
[122]. Instructing patients about the relationship
between an excessive use of acute medications and head-
ache progression is an important preventive measure.
The results from multiple studies have shown that most
MOH patients have little to no knowledge about exces-
sive drug intake headache chronification. Many patients
however received correct information, but often did not
remember or had not fully understood the message
[123–125]. As in other patients with chronic pain condi-
tions, MOH patients seem mainly focused on the side
effects related to the acute pain medications, including
gastrointestinal bleeding, kidney damage, and liver im-
pairment. They are often surprised when they learn that
the excessive use of acute pain drugs might increase
headache frequency, leading to MOH [126]. This is due
to the fact that for many MOH patients the symptomatic
medications are merely the drugs they need to relief
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their pain, and the only way that could bring relief to
the impact on their lives [127].
According to this evidence, developing information
campaigns and strategies to target patients at risk, pref-
erably before MOH onset, represents an essential object-
ive in headache medicine. In German headache centers,
a brochure on medication overuse was effective in pre-
venting the development of MOH in people with mi-
graine and frequent medication use [128]. Primary care
is the best setting for prevention and initial treatment of
MOH, since most MOH patients consult their general
practitioner (GP) for headache (80%) [129]. GPs can play
a key role in providing patient education about medica-
tion use and modifiable risk factors, such as stress, daily
smoking, physical inactivity, and obesity [82]. GPs are
also capable of prescribing first-line headache prophy-
laxis in episodic patients when required.
MOH patients often bypass medical advice by using
over-the-counter medication. A study recruited patients
in pharmacies and found that only 14.5% were ever ad-
vised to limit intake frequency of acute headache treat-
ments [130]. In a recent Swedish study investigating the
knowledge of 326 pharmacists on headache treatment,
only 8.6% demonstrated knowledge that overuse of all
types of acute headache medications could lead to the
development of MOH [131].
In 2016, the Danish national awareness campaign for
MOH was conducted to reach the general public, GPs,
and pharmacists. Online resources, print media, radio
interviews, and a television broadcast were used to bring
key messages such as overuse of pain medication can
worsen headaches, pain medication should be used
rationally, and medication overuse headache is treatable.
The survey showed an increase in percentage of the
public who knew about MOH [132].
Withdrawal as the first phase of treatment
Despite the large controversies about whether medication
overuse should be regarded as a cause or a consequence
of headache chronification, to date, the worldwide consen-
sus agrees that (ideally complete) withdrawal of acute
painkilling drugs is the approach of choice for the acute
management of MOH patients [133–135]. In a recent ran-
domized controlled open-label trial, complete discontinu-
ation of acute medications came forward as the most
effective detoxification program compared to restricted
drug intake [136]. Drug discontinuation is advised in most
headache treatment guidelines, including guidelines for
primary care [137–139] . The crucial therapeutic aspect of
withdrawal is that, on the one hand, it is an occasion for
the physician to help the patient decrease or stop the use
of acute medication, while potentially initiating a new pre-
ventive therapy. It is an opportunity for the patient to re-
consider his or her headache history, to discover the link
with medication overuse and to be guided by the physician
in the process of withdrawal [140].
Drug discontinuation is performed variously in differ-
ent headache clinics. In terms of timing, no studies have
investigated the abrupt interruption versus the progres-
sive cessation of the overused drugs, but it is widely
agreed that for triptans, ergots, combination analgesics,
simple analgesics, and NSAIDs the abrupt withdrawal is
the treatment of choice, since these medications do not
cause severe withdrawal symptoms [137]. On the oppos-
ite, a gradual drug reduction is the best option with bar-
biturates, benzodiazepines, and opioids [137].
Withdrawal symptoms (e.g. headache, nausea, vomiting,
arterial hypotension, tachycardia, sleep disturbances, etc)
generally last for 2–10 days. Seizures or hallucinations
are rare, even in patients who are barbiturate abusers.
The withdrawal phase is shorter in subjects who exces-
sively use triptans [141].
Certain studies have demonstrated that simple infor-
mation and advice may be enough to achieve headache
improvement in many MOH patients [142, 143]. In the
Brief Intervention for Medication-Overuse Headache
(BIMOH) study, a sample of MOH patients received a
brief intervention of education on medication overuse
from their GPs. After 3 months, headache and medica-
tion days were reduced by 7.3 days/month, and chronic
headache resolved in 50% of the cases [129]. The effect-
iveness of this brief intervention was confirmed at
6 month-follow up: headache and medication days were
reduced by 5.9 days/month, and chronic headache re-
solved in 63% [144].
Deciding on the setting for withdrawal is a key point of
MOH treatment. The choice between outpatient and in-
patient withdrawal has to consider many factors, including
the patient’s motivation, the duration of the overuse, the
type of overused drugs, possible previous detoxification
failures and comorbidities. An outpatient detoxification
can be the preferred setting for highly motivated patients,
with a short duration of overuse of simple analgesics, and
whose everyday life make an inpatient withdrawal unsuit-
able [145]. Instead, inpatient withdrawal therapy is recom-
mended for patients overusing more complex analgesics
(such as opioids, tranquilizers, or barbiturates), long dur-
ation of overuse, previous failure to withdraw drugs as
outpatients and in more complex clinical situations (e.g.
psychiatric comorbidities) [137]. No standardized thera-
peutic protocol for medication withdrawal is accepted
worldwide. Different strategies are employed in clinics
such as intravenous hydration, rescue medications such as
IV aspirin and IV dihydroergotamine, symptomatic drugs
other than those overused, and drugs for withdrawal
symptoms including antiemetics (e.g. metoclopramide),
clonidine, benzodiazepines, and corticosteroids [36, 146–
150]. Considering corticosteroids, there is low evidence
Vandenbussche et al. The Journal of Headache and Pain  (2018) 19:50 Page 7 of 14
for change in various headache outcome measures (i.e.
use of rescue medication, days with severe or moderate
headache, days without headache, headache days, and
headache frequency) [151, 152]. Evidence in favor of in-
patient withdrawal comes from an observational study
showing statistically significant improvement of quality of
life, depression and anxiety at 6-month follow-up [153].
Furthermore, it is recognized that a proper therapeutic ap-
proach to MOH requires a multistep and multidisciplinary
program [154, 155]. The “COMOESTAS” consortium pro-
vided an expert consensus protocol in four centers from
Europe and two centers in Latin American. The results
show that after multiphasic and personalized treatment,
two thirds of patients were no longer overusers and al-
most half reverted to an episodic headache syndrome over
a six-month period [156].
Prophylaxis
The initiation of preventative therapy is a fundamental
therapeutic step to prevent episodic headache converting
into a chronic condition. However, the question remains
unresolved whether starting prophylactic treatment at the
beginning of withdrawal or awaiting the effect of detoxifica-
tion is the most effective approach. Certain authors recom-
mend that in non-complicated MOH patients, the decision
to start preventive treatment may be postponed for two to
3 months following withdrawal. On the contrary, patients
who already have a high frequency of headaches before
medication overuse and who have been previously treated
with more than one preventive treatment, might need early
prophylaxis [157]. Other clinicians believe that the detoxifi-
cation can be effective without an immediate prophylaxis
[126]. To date, as confirmed in a recent meta-analysis of
randomized controlled trials on the effect of prophylactic
therapies (i.e. valproate, nabilone, onabotulinumtoxinA,
topiramate, amitriptyline), there is not a preventative drug
that has demonstrated superiority to other therapies in a
qualitative, appropriately designed study [152]. The results
of randomized controlled trials with patients affected by
chronic migraine and MOH suggest the use of onabo-
tulinumtoxinA and topiramate without early discon-
tinuation. However, the quality of the data is limited
due to the fact that it is based on post hoc analysis
[158]. A future role for monoclonal antibodies targeting
the CGRP pathway is to be awaited [159]. Ultimately,
the identification of proper prophylaxis should be
driven by clinical history, comorbidity, contraindica-
tions and side effects of the possible drugs [126].
Treatment of comorbidities
Comorbidities have important implications for the manage-
ment of MOH in daily clinical practice. Co-existence of
mood disorders may lead to poorer adherence of headache
treatment, leading to unsuccessful headache treatment.
Comorbid psychiatric disorders add to overall burden and
reduced quality of life in headache patients and may lead to
poorer outcomes after treatment. Therefore, screening pa-
tients for anxiety and depression, is important for clinical
outcomes and for trials studying MOH. Lastly, attention for
metabolic disturbances or unhealthy lifestyle behavioural
aspects, such as obesity, smoking and inactivity, in daily
practice is probably beneficial not only for general health
but also for headache outcomes. As these are mostly modi-
fiable factors, it is reasonable to discuss and treat these con-
ditions accordingly.
Prognosis
In general, overuse of acute treatment can lead to a poor
prognosis of chronic headache and lower quality of life
by itself [160]. The outcome for MOH patients with-
drawing from their acute treatments has been reported
in multiple studies. An accepted endpoint for good re-
sponse to therapy is a ≥ 50% reduction from baseline
headache frequency and/or headache index [161]. Suc-
cessful withdrawal has been found in around 50–70% of
MOH patients after 1 year [68, 162–170]. Retaining full
withdrawal after 1 year was found to be a good predictor
for long-term success [171, 172]. In studies with
long-term evaluations up to 6 years, relapsing rates be-
tween 40 and 50% were found [163, 164, 173–177]. A
successful withdrawal leads to a better response for
prophylactic treatment, even in patients with little im-
provement in headache frequency [178]. Multiple pre-
dictors of relapse have been documented. Patients with
tension-type headache have a higher relapse risk [162–
164, 173, 179]. A longer duration of regular intake is a
predictor for relapse [174, 180]. Patients who kept over-
using medication in the long-term had a poor response
to withdrawal therapy and had a higher frequency of
chronic headache [171]. Risk factors for relapse in
short-term (1 year) were: high number of acute treat-
ments, smoking, alcohol consumption and return to
overused drugs [181]. Patients withdrawn from triptans
have a lower risk for relapse, while combined drug ther-
apy had a higher relapse rate [163, 179, 182]. Codeine
containing drugs, low self-reported sleep quality and
high self-reported bodily pain are probable predictors
for poor outcome after 1 yr [170].
Debates in MOH
The idea of MOH is well-known and widespread in
clinics worldwide. By using the operational criteria for
MOH in the ICHD-3 classification, clinicians are able to
diagnose MOH as early as first clinic visits in order to
guide patients in cutting down the amount of frequently
used analgesics.
The evidence in favor of the disorder MOH is substan-
tial since global research has gradually improved our
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knowledge on the complexity of the disorder. Consistent
observations from population-based longitudinal studies
by headache experts in expertise centers worldwide, have
established the entity of MOH in a considerable amount
of headache patients. Research on the pathophysiological
mechanisms is steadily unravelling the different pro-
cesses involved with analgesic overuse in headache syn-
dromes. Agreement in findings from imaging studies for
entity-specific alterations in the brain have been pub-
lished, although the amount of data is still limited and
needs further research [86, 87]. Furthermore, the results
from neuroimaging suggest that neuroplasticity exists
and that specific imaging findings can be predictive for
the outcome after withdrawal. Lastly, the field of genet-
ics in MOH is in development, reaching out to a more
personalized approach for MOH [159].
However, it is important to raise awareness on the
current limitations to the state of literature on MOH.
Questions need to be put forward on how to analyse the
phenomenon of deteriorating headaches with the use of
analgesics. Mostly, the disorder is seen in patients with
pre-existing headache disorders and therefore analysing it
as a complication to these conditions is reasonable. Given
the potential for the onset of chronic headache after regu-
lar intake of analgesics for other medical conditions, MOH
can be conceptualized as a secondary headache disorder.
But reminding ourselves to patients who experience in-
creasing headache severity and frequency without drug
overuse, the overuse of analgesics can be seen as a mere
epiphenomenon to the primary headache disorder, a cyc-
ling disorder with good and bad phases, for which treat-
ment of the headache syndrome without detoxification is
required [155, 183]. The scientific community has not yet
come to the end of this discussion. The lack of robust
evidence from high-quality, well-designed and large
randomized controlled clinical trials on MOH is im-
portant in this analysis [184]. Withdrawal studies over
the years have delivered evidence of moderate quality,
mostly due to the lack of control groups, lack of
randomization, difficulties in adequate blinding and
often high dropout rates [158, 184]. Furthermore, evi-
dence in favour of starting prophylactic treatment in
MOH comes from post-hoc analysis without adequate
power [134, 158]. One of the most critical aspects of
MOH treatment concerns discontinuation of the symp-
tomatic medication. This concept is installed by using
observational data and specialist consensus, not on
solid level of evidence from large and well powered ran-
domized, blinded trials [137, 139]. Because of the huge
burden of disease for patients, larger and high-quality
interventional trials on the efficacy of treatments are
needed [158, 184]. This is complicated by a significant
limitation. For an individual patient, the existence of
MOH can neither be proven nor invalidated due to the
lack of pathognomonic clinical aspects or a clinical use-
ful biomarker, and therefore studies will still rely on
consensus criteria.
The diagnostic criteria for MOH in the international
classification remain fuel for debate, even after three edi-
tions and multiple decades. The discussion whether
MOH has a rightful place in the classification as a sec-
ondary headache disorder is interesting and relevant.
The current ICHD-3 criteria do not denominate MOH
to be a ‘transformed’ version of a primary headache dis-
order, but instead describe a concurrent medical prob-
lem occurring with an underlying headache disorder.
The diagnosis is neither a definitive claim on the cause
of a progressive headache disorder either. It has a more
moderate approach to the occurrence of medication
overuse than previous clinical criteria. Furthermore, the
current classification uses clinical features that do not
touch upon on the underlying neurobiological processes
and has rigid elements such as the cut-off of 15 days per
month. These elements may need to be revisited when
new evidence becomes available in the future [23].
Finally, different authors discussed the previous,
current and possible future terminology used in the field
of MOH. In terms of semantics, the term “medication-o-
veruse headache” was challenged by Solomon et al. in
2011 [185]. MOH has a potential stigmatizing and (self-)
blaming message to patients that can put pressure on a
good patient-physician relationship. Appellations as “iatro-
genic headache” and “medication-overtreatment head-
ache” have a potential to lay blame on healthcare
providers [184]. On the other hand, terminology such as
“medication misuse headache”, “medication abuse head-
ache”, “drug abuse headache” also carry a clue of leaving
patients responsible for the development of the situation.
Hence Solomon et al analyzed possible mechanism-based
definitions, for instance “medication-induced head-
ache”, “feed-forward headache”, “drug-transformed (or
amplified) headache” and suggested implicating the
term “medication-adaptation headache” as the most
appropriate [185].
To summarize, after analyzing the literature on
MOH, it is our understanding that for clinicians in
daily practice, the evaluation of the frequency and
quantity of use of analgesics in patients with head-
ache syndromes is a key component of medical as-
sessment in headache disorders. Side effects of
analgesic overuse must be actively evaluated and
treated accordingly. However, MOH is not to be diag-
nosed rapidly without further intellectual persever-
ance, since a false-positive diagnosis of MOH can
lead to misdiagnosis. Other secondary causes of head-
ache may lead to headache progression in conjunction
with medication overuse. We therefore state that a
critical appraisal of the entity of MOH is required in
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every individual patient. A thorough clinical approach
with exact history taking to detect temporal relation-
ships, and clinical examination focused on neuro-
logical deficits, remain the foremost necessary assets
for clinicians in the absence of accurate technical
tools.
Conclusion
Research in MOH is moving forward and is discovering
the mechanisms underlying headache progression and
medication overuse. Whether MOH is a definitive dis-
tinct entity, a complication in the pathophysiology of
primary headache disorders or an epiphenomenon in the
natural course of headache disorders is still up for de-
bate. Since methodology is improving and world-wide
collaborative efforts are being established, it is clear that
high-quality research will help us to resolve multiple
questions stated above. Ultimately, by making scientific
progress, we are hopeful that new evidence will help cli-
nicians to make the right choices for patients suffering
highly disabling headaches and comorbidities.
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